Government of Canada
Symbol of the Government of Canada

Common menu bar links

Translating Basic Science Through Capacity-Building and Private Sector Technology Development

Objectives

  • Building site capacity in low-and-middle-income countries to conduct HIV vaccine clinical trials;
  • Strengthening the capacity of researchers and research institutions to conduct high-quality clinical trials; and
  • Establishing a new transfer payment fund to encourage private sector participation in technology development that would contribute to the development of an HIV vaccine.

Activities

  • Provide support to the Global Health Research Initiative (GHRI) to implement the HIV Prevention Trials Capacity Building Program Grants to strengthen the capacity and leadership of African researchers and research institutions to conduct future HIV/AIDS prevention trials with a focus on HIV prevention technologies, particularly vaccines;
  • Provide direct project management support services along with access to technical information and knowledge to assist researchers in transforming applied and preclinical research into clinical trial studies;
  • Provide funding to selected HIV vaccine developers to enable access to existing private sector facilities to manufacture clinical trial lots of HIV vaccine candidates;
  • Encourage private sector Small and Medium Enterprise participation in projects that will contribute to the development of an HIV vaccine under a new program to be delivered under the National Research Council's Industrial Research Assistance Program (NRC-IRAP).

Outcomes

  • Greater number of early stage clinical trials being conducted in low-and-middle-income countries;
  • Efficient and timely transition from preclinical research into clinical trial studies, ultimately increasing the body of knowledge with respect to an HIV vaccine in Canada and low-and-middle-income countries;
  • Increased number of clinical trial lots manufactured for promising HIV vaccine candidates in low-and-middle-income countries;
  • Strengthened clinical trial capacity in Canada and low-and-middle-income countries; and
  • Advance the development of new and innovative HIV/AIDS-related technologies for the prevention, treatment, and diagnosis, including production and multi-purpose technologies, that have potential applications in HIV/AIDS.